Preparation
Each film coated tablet contains Linagliptin INN 5 mg.
Indication
Linastar-5 is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Contraindication
Hypersensitivity to the active substance or to any of the excipients.
Dosage & Administration
The recommended dose of Linastar-5 is once daily. No dosage adjustment is required for hepatic or kidney impaired patients.
Side Effect
Hypoglycemia, headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heart beat, sweating, stuffy or runny nose and sore throat.
Precaution
Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Drug Interaction
P-glycoprotein/CYP3A4 inducer: The efficacy of Linagliptin may be reduced when administered in combination (e.g., with rifampin). Sulfonylurea should cautiously use during treatment with Linagliptin.
Use Children
This combination is not recommended for use in children & adolescent under 18 years.
Use Pregnancy Lactation
Pregnancy category B. There are no adequate and well controlled studies in pregnant women. So, Linagliptin tablets should be used during pregnancy only if clearly needed.
Packaging
Each box contains 3X10 tablets in alu-alu blister pack.
Storage
Store below 30 °C, keep in a dry place and protected from light. Keep all medicines out of the reach of children.
